Clinical Trials Logo

Sepsis clinical trials

View clinical trials related to Sepsis.

Filter by:

NCT ID: NCT05939245 Recruiting - Clinical trials for Acute Kidney Injury Due to Sepsis

Comparison of Plasma Neutrophil Gelatinase-Associated Lipocalin (pNGAL) Level in De-resuscitation With Furosemide Group and Control Group

Start date: July 24, 2023
Phase: N/A
Study type: Interventional

The impact of early de-resuscitation with furosemide on patients with sepsis-related acute kidney injury using pNGAL as the parameter of acute kidney injury.

NCT ID: NCT05930418 Recruiting - Sepsis Clinical Trials

Cardiovascular Magnetic Resonance Prognosticators in Pediatric Oncology Patients With Sepsis

Start date: May 20, 2023
Phase: N/A
Study type: Interventional

The overall purpose of this protocol is to identify subacute sepsis-associated cardiac disease in pediatric patients with cancer by CMR and evaluate the CMR findings during their follow-up. This will help inform heart failure management decision making. Evidence of dysfunction or elevated T2 values may inform adjustment of afterload reduction and beta blocker administration, and elevated ECV findings will suggest the need for increased surveillance for diastolic dysfunction. Primary Objectives: (Feasibility Phase) To determine the feasibility of cardiac MRI without anesthesia in the immediate post-sepsis period in children with cancer. CMR scanning will be completed within 10 days of presentation - this will allow us to ensure that possible hemodynamic or respiratory instability and renal dysfunction has resolved prior to transport to the MRI scanner during the most acute phase of illness. (Completion Phase) To estimate the frequency of subacute sepsis-associated cardiac disease, including myocardial inflammation and dysfunction, in the post-acute phase (within 10 days of presentation) of severe sepsis in children with cancer

NCT ID: NCT05922371 Recruiting - Sepsis Clinical Trials

ObsErvational Study of the Practical Cinical UTility of the NuQ.® H3.1 Nucleosome Levels in Adult Patients With Sepsis to Facilitate Early Diagnosis and Prognostication. (EPICETUS)

EPICETUS
Start date: December 18, 2023
Phase:
Study type: Observational

This is a study to evaluate the diagnostic performance of the investigation NuQ. (R) H3.1 nucleosome assay as a diagnostic marker of sepsis in a population of patients admitted to critical care with signs suspicious of infection and consistent with the sepsis 3 definition. These patients will be compared to a group of adult surgical patients free from infection that are undergoing their first cardiac surgery.

NCT ID: NCT05921825 Not yet recruiting - Sepsis Clinical Trials

Red Cell Distribution Width and Lactate Albumin Ratio as Prognostic Markers for Mortality in Sepsis and Septic Shock

Start date: July 1, 2023
Phase:
Study type: Observational

The aim of this study is to find the utility of red cell distribution width and lactate/albumin ratio as prognostic markers in sepsis and septic shock patients.

NCT ID: NCT05919966 Completed - Clinical trials for Central Line-associated Bloodstream Infection (CLABSI)

The Association Between Chlorhexidine Bathing and Central Line-Associated Infections in Medical Intensive Care Units

Start date: April 12, 2023
Phase:
Study type: Observational

We conducted a retrospective observational cohort study assessing the relationship between regular bathing using 2% CHG wipes every other day and the occurrence of central line-associated infections (CLABSI) in patients within the medical intensive care unit (MICU).

NCT ID: NCT05918705 Recruiting - Clinical trials for Sepsis-associated Encephalopathy

Optic Nerve Sheath Diameter / Eyeball Transverse Diameter Ratio and Prognosis of Sepsis Associated Encephalopathy

Start date: March 1, 2023
Phase:
Study type: Observational

Sepsis is associated with a mortality rate of 20-25%, with significant increase in case of associated comorbidities or shock. SAE is one of the most common forms of encephalopathy encountered in critically ill patients, with increased ICP as a possible underlying mechanism. Many studies revealed that ONSD is a valuable ICP monitoring tool. Also, ONSD/ETD ratio, according to previous studies, seemed to be more reliable than ONSD alone in predicting neurological outcomes of comatosed patients. The present study will assess the correlation between US-ONSD/ETD ratio and the prognosis of SAE in critically ill patients.

NCT ID: NCT05914571 Not yet recruiting - Clinical trials for Artificial Intelligence

Artificial Intelligence With Determination of Central Venous Catheter Line Associated Infection Risk

Start date: July 2023
Phase:
Study type: Observational

The goal of this methodological, retrospective and prospective study is to; it is a tool to develop a risk estimator tool to detect risk gaps in individuals using artificial intelligence technology that is dangerous for those with CVC in adult intensive care patients, to test risk level estimation frameworks and to evaluate outcomes in the clinic. In our study, it is also our aim to protect, to present the security measures to prevent the risk of CVC with an artificial intelligence model, in an evidence-based way. The main question[s]it aims to answer are: - Can the risk of CVC-related infection be determined in adult intensive care patients using artificial intelligence? - To what degree of accuracy can the risk of CVC-associated infection be determined in adult intensive care patients using artificial intelligence? - What are the nursing practices that can reduce the risk of CVC-related infections? Methodology to develop an artificial intelligence-based CVC-associated infection risk level determination algorithm, retrospective using data from Electronic Health Records (EHR) patient data and manual patient files between January 2018 and December 2022 to create the algorithm and test the model accuracy, and the development stages of the model After the completion of the model, up-to-date data were collected for the use of the model and it was planned to be done prospectively.

NCT ID: NCT05914480 Not yet recruiting - Sepsis Clinical Trials

Sepsis in ICU:Causes and Outcomes in Diabetics and Non Diabetics

Start date: July 2023
Phase:
Study type: Observational

Identify prevalence of sepsis in ICU of Assiut university hospital 2.Clarify different causes of sepsis in patients admitted to ICU . 3.Compare causes and outcomes of sepsis between diabetics versus non diabetics . 4.Screening for the co1.mmonest organism causing sepsis in critically ill patients .

NCT ID: NCT05914428 Recruiting - Sepsis Clinical Trials

Biomarkers to Predict Acute Respiratory Distress Syndrome(ARDS) in Patients With Sepsis

Start date: June 13, 2023
Phase:
Study type: Observational

Sepsis-induced acute respiratory distress syndrome (ARDS) is a life-threatening acute inflammatory lung injury, associated with increased pulmonary microvascular permeability, increased lung weight, and loss of aerated lung tissue.Despite advances in critical care, no established and targeted treatment for ARDS, contributing to a persistently high mortality rate of 34% to 45%. Therefore, exploring novel therapeutic targets for septic ARDS is of paramount importance.Acetaldehyde dehydrogenase 2 (ALDH2) is a mitochondrial enzyme that serves as the primary toxic aldehyde scavenger and is expressed in various cells, including neutrophils. The ALDH2 rs671 single nucleotide polymorphism, leading to an approximate 90% decrease in ALDH2 enzymatic activity, is implicated in occurrence of macrovascular conditions, such as coronary artery disease, pulmonary arterial hypertension, and aortic aneurysm or dissection.An array of studies has delved into role of ALDH2 in regulating cellular processes, including inflammation, autophagy, apoptosis, necrosis,efferocytosis and pyroptosis.but whether it associated with the incidence of septic-ARDS remains unknown.The aim of this study was to determine whether the ALDH2 rs671 single nucleotide polymorphism was associated with the incidence of septic-ARDS.

NCT ID: NCT05912413 Recruiting - Sepsis Clinical Trials

Predicton of Sepsis Recovery Performance Subtypes Pilot Study

Start date: July 11, 2023
Phase:
Study type: Observational

This study addresses critically ill sepsis patients' current literature reports of ongoing post-hospital discharge weakness and hospital readmissions. This study is aimed at capture and interpretation of a complex set of tests, administered during a subject's sepsis functional recovery trajectory, particularly capturing hospital readmission's effects on survivors' physical function recovery.